Frequency: Every 3 Months: every 3 months
Frequency: Every 6 Months: every 6 months
Imaging Modality: Chest Radiograph (CXR): Chest radiograph (CXR)
Imaging Modality: Chest CT: Chest computed tomography (CT)
Following treatment for a primary extremity sarcoma, patients remain at risk for the development of local and systemic disease recurrence. Metastasis (distant recurrence) to the lung is the most frequent single location of disease recurrence in sarcoma patients, occurring in almost half of all patients. Therefore, careful post-operative surveillance is an integral element of patient care. However, the detection of metastases does not necessarily affect long-term survival and may negatively impact quality of life. Surveillance strategies have not been well researched and have been identified as the top research priority in the extremity sarcoma field. Using a 2X2 factorial design to maximize efficiency and reduce overall trial costs, the SAFETY trial randomized 310 extremity soft-tissue sarcoma (STS) patients to determine the effect of surveillance strategy on overall patient survival after surgery for a STS of the extremity by comparing the effectiveness of both surveillance frequency (every 3 vs. every 6 months) and imaging modality (CT scans vs. chest radiographs).
| Facility | City | Region | Status |
|---|---|---|---|
| University of California Davis Medical Center | Sacramento | California | |
| Hartford HealthCare | Hartford | Connecticut | |
| University of Florida Health Shands Hospital | Gainesville | Florida | |
| UChicago Medicine | Chicago | Illinois | |
| Parkview Cancer Institute | Fort Wayne | Indiana | |
| Holden Comprehensive Cancer Center | Iowa City | Iowa | |
| Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | |
| Albany Medical Center | Albany | New York | |
| NYU Langone Orthopaedic Hospital/Perlmutter Cancer Center | New York | New York | |
| Montefiore Medical Center | The Bronx | New York | |
| Cleveland Clinic | Cleveland | Ohio | |
| Oregon Health and Science University Hospital | Portland | Oregon | |
| Allegheny Health Network Research Institute | Monroeville | Pennsylvania | |
| Texas Tech Health Sciences Center | El Paso | Texas | |
| Huntsman Cancer Institute | Salt Lake City | Utah | |
| Fred Hutchinson Cancer Center | Seattle | Washington | |
| Hospital Universitario Austral | Buenos Aires | Argentina | |
| St. Vincent's Hospital Melbourne | Fitzroy | Melbourne | |
| LKH - Universitätsklinikum Graz | Graz | Austria | |
| Cliniques Universitaires Saint-Luc | Brussels | Belgium | |
| Hospital de Clínicas de Porto Alegre | Porto Alegre | Brazil | |
| Nova Scotia Health | Halifax | Nova Scotia | |
| Juravinski Hospital and Cancer Centre | Hamilton | Ontario | |
| The Ottawa Hospital | Ottawa | Ontario | |
| Mount Sinai Hospital | Toronto | Ontario | |
| Hôpital Maisonneuve-Rosemont | Montreal | Quebec | |
| McGill University Health Centre | Montreal | Quebec | |
| Hôtel Dieu du Quebec | Québec | Quebec | |
| Helios Klinikum Berlin | Berlin | Germany | |
| Centro Traumatologico Ortopedico Hospital | Turin | Italy | |
| University Malaya Kuala Lumpur | Kuala Lumpur | Malaysia | |
| Leiden University Medical Center | Leiden | Netherlands | |
| Centro Hospitalar e Universitario de Coimbra | Coimbra | Portugal | |
| Hospital Vall d'Hebron | Barcelona | Spain | |
| Karolinska University Hospital | Stockholm | Sweden |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03944798 on ClinicalTrials.gov ↗ ← All trials in Canada